BioSpace News Archive

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development.

Etiometry, the leader in clinical decision-support software, announced its IVCO2 Index™ was cleared by the Food and Drug Administration for use with neonatal ICU patients under 2kg, who are especially vulnerable to the effects of hypercapnia.

IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the “Company” or “IntelGenx”) today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm ® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”).

scPharmaceuticals Inc. today announced that the Company has received positive Type C meeting feedback from the US Food and Drug Administration (FDA) regarding the potential expansion of the FUROSCIX®.

Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for elraglusib for treatment of patients with pancreatic cancer.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that the company will be participating in several conferences during August.

Comera Life Sciences Holdings, Inc. announced that it has executed a definitive agreement to complete a $4.1 million private placement of shares of its common stock, and accompanying warrants to purchase shares of its common stock, to existing stockholders at a purchase price of $0.51125 per share.

INmune Bio announced today that RJ Tesi, MD, CEO and David Moss, Chief Financial Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 7 – 8, 2023.

Coeptis Therapeutics Holdings, Inc. announced that it has submitted a 513(g) request to the U.S. Food and Drug Administration (FDA) for an in vitro companion diagnostic test designed to be used with anti-CD38 monoclonal antibody therapies.

Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston.